These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 30702337)

  • 1. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
    Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
    DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
    Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
    Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
    Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
    Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro.
    Normann LS; Aure MR; Leivonen SK; Haugen MH; Hongisto V; Kristensen VN; Mælandsmo GM; Sahlberg KK
    Sci Rep; 2021 May; 11(1):10893. PubMed ID: 34035375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic microRNA activity identifies therapeutic targets in trastuzumab-resistant HER2
    Decker JT; Hall MS; Blaisdell RB; Schwark K; Jeruss JS; Shea LD
    Biotechnol Bioeng; 2018 Oct; 115(10):2613-2623. PubMed ID: 29981261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of miR-770-5p in trastuzumab response in HER2 positive breast cancer cells.
    Noyan S; Gurdal H; Gur Dedeoglu B
    PLoS One; 2019; 14(4):e0215894. PubMed ID: 31009516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
    Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
    Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
    Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
    PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
    Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing
    Zhang P; Yang Y; Qian K; Li L; Zhang C; Fu X; Zhang X; Chen H; Liu Q; Cao S; Cui J
    J Biol Chem; 2020 Oct; 295(41):14140-14152. PubMed ID: 32690611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
    Pereira TDSF; Brito JAR; Guimarães ALS; Gomes CC; de Lacerda JCT; de Castro WH; Coimbra RS; Diniz MG; Gomez RS
    J Oral Pathol Med; 2018 Jan; 47(1):78-85. PubMed ID: 29032608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
    Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance.
    De Cola A; Volpe S; Budani MC; Ferracin M; Lattanzio R; Turdo A; D'Agostino D; Capone E; Stassi G; Todaro M; Di Ilio C; Sala G; Piantelli M; Negrini M; Veronese A; De Laurenzi V
    Cell Death Dis; 2015 Jul; 6(7):e1823. PubMed ID: 26181203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer.
    Lyu H; Wang S; Huang J; Wang B; He Z; Liu B
    Cancer Lett; 2018 Apr; 420():97-108. PubMed ID: 29409974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer.
    Othman MS; Elabbasy MT; Aref AM; Altaleb AA; Mohammed MH; Soliman DAM; El-Khazragy N
    Technol Cancer Res Treat; 2024; 23():15330338241292226. PubMed ID: 39429192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.